TKD-007

TKD-007 is an investigational small molecule nasal spray developed by Therakind for the prevention of common cold and influenza infections. The product is designed to be administered via the intranasal route, potentially acting at the primary site of respiratory viral entry to provide a protective effect. As part of Therakind's pipeline, which focuses on optimizing treatments for pediatric and geriatric populations, TKD-007 represents a preventative approach to respiratory illness. While the specific active pharmaceutical ingredient and molecular target have not been publicly disclosed, the program is currently in the early stages of development.